Galmed Pharma (GLMD) Announces Late-Breaking Abstract on Aramchol to be Presented at AASLD
Article
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH"), announced today that a late-breaking abstract on the one-year results of a Phase 2b study of Aramchol in patients with NASH will be presented by the Company at the American Association for the Study of Liver Diseases – The Liver Meeting®, taking place November 9–13, 2018 in San Francisco, California. The oral session will be presented by Prof. Vlad Ratziu, France, principal investigator of the ARREST trial. More data on Aramchol anti fibrotic effect will be presented in a poster presentation.
ARREST is a multicenter, Phase 2b, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses (400 and 600 mg tablets) in patients with NASH confirmed by liver biopsy who were overweight or obese and who were pre- diabetic or type II diabetic. Top line results from the study were released by Galmed on June 12, 2018.
Oral Abstract Presentation Details:
Date: Tuesday, November 12, 2018Time: 8:00am Pacific TimeLocation: Hall D - General Session, Moscone Center, North and South BuildingsPublication #: LB-5Session Title: Late-Breaking Abstract Oral Session IIPresentation Type: Oral, Late-Breaker SessionTitle: One-Year Results of the Global Phase 2b Randomized Placebo-Controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturase Inhibitor, in Patients with NASH
Poster Abstract Presentation Details:
Date: Monday, November 13, 2018Time: 8:00am – 5:30pm Pacific TimePublication #: 2060Poster Session Title: Steatohepatitis: ExperimentalPresentation Type: PosterTitle: Aramchol downregulates SCD1 and induces PPAR g in hepatic stellate cells to attenuate cellular activation and fibrogenesis.